Vaxcyte, Inc. (PCVX)

Vaxcyte Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-946.53	-766.63	-463.93	-402.27	-223.49	-100.08
Depreciation & Amortization	25.84	24.86	15.85	10.17	9.45	3.46
Stock-Based Compensation	146.19	138.85	84.82	48.76	23.65	10.73
Other Adjustments	-38.58	-49.2	-34.47	-34.78	7.05	1.5
Changes in Accounts Payable	48.8	19.91	34.58	11.23	2.9	-12.47
Changes in Accrued Expenses	74.31	39.33	-49.08	90.67	8.72	-0.77
Changes in Other Operating Activities	-79.96	-62.69	-40.4	-20.58	1.12	-23.76
Operating Cash Flow	-769.93	-655.58	-452.63	-296.79	-170.6	-121.39
Capital Expenditures	-45.02	-56.97	-119.16	-67.88	-5.84	-6.56
Sale of Property, Plant & Equipment	-	-	-	-	-	0.03
Purchases of Investments	-1,481	-1,212	-3,087	-1,330	-102.75	-336.34
Proceeds from Sale of Investments	1,607	1,706	1,200	624.46	183.17	130.56
Investing Cash Flow	80.63	437.35	-2,006	-773.31	74.59	-212.31
Issuance of Common Stock	617.83	13.01	2,463	643.69	862.41	17.8
Repurchase of Common Stock	-15	-10.99	-14.29	-3.88	-0.86	-
Net Common Stock Issued (Repurchased)	602.84	2.01	2,449	639.81	861.55	17.8
Financing Cash Flow	602.84	2.01	2,449	639.81	861.55	17.8
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.6	2.44	0.43	-6.69	0.14	-0.44
Net Cash Flow	-85.86	-213.77	-9.36	-436.97	765.67	-316.34
Free Cash Flow	-814.94	-712.55	-571.79	-364.67	-176.44	-127.95
Free Cash Flow Per Share	-5.95	-5.24	-4.69	-3.75	-2.72	-2.46
Levered Free Cash Flow	-922.56	-802.19	-622.14	-378.65	-207.14	-140.18
Unlevered Free Cash Flow	-1,065	-959.24	-727.76	-444.43	-215.91	-143.77

Updated May 6, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q